4.40
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Can Vanda Pharmaceuticals Inc. stock deliver surprise earnings beatWeekly Trade Report & High Yield Equity Trading Tips - newser.com
Smart tools for monitoring Vanda Pharmaceuticals Inc.’s price action2025 Key Lessons & Safe Entry Trade Signal Reports - newser.com
Will Vanda Pharmaceuticals Inc. (VM4) stock remain on Wall Street radar2025 Market Outlook & Daily Stock Trend Watchlist - newser.com
FY2025 EPS Estimates for VNDA Boosted by Cantor Fitzgerald - MarketBeat
Backtesting results for Vanda Pharmaceuticals Inc. trading strategiesJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Assessing Vanda Pharmaceuticals (VNDA) Valuation After Q3 2025 Growth and Updated FDA Milestones - Yahoo Finance
Visualizing Vanda Pharmaceuticals Inc. stock with heatmapsMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
Is Vanda Pharmaceuticals Inc. stock safe for conservative investorsMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
How institutional buying supports Vanda Pharmaceuticals Inc. stock2025 Top Decliners & Smart Swing Trading Techniques - newser.com
News impact scoring models applied to Vanda Pharmaceuticals Inc.July 2025 Recap & Free Daily Entry Point Trade Alerts - newser.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Vanda Pharmaceuticals Reports Strong Sales Growth and Pipeline Progress - MSN
Cantor Fitzgerald Cuts Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target to $11.00 - MarketBeat
Jim Cramer on Vanda Pharmaceuticals: “I’m Going to Bless That One as Your Spec” - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Q3 Earnings Preview - MSN
Published on: 2025-10-31 05:46:53 - newser.com
Applying big data sentiment scoring on Vanda Pharmaceuticals Inc.2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
Real time pattern detection on Vanda Pharmaceuticals Inc. stockQuarterly Profit Review & Consistent Return Strategy Ideas - newser.com
Vanda Pharmaceuticals Inc. stock retracement – recovery analysis - newser.com
Will Vanda Pharmaceuticals Inc. stock recover after recent dropShare Buyback & Weekly Watchlist for Consistent Profits - newser.com
Can Vanda Pharmaceuticals Inc. recover in the next quarterWeekly Investment Report & Reliable Entry Point Alerts - newser.com
Is Vanda Pharmaceuticals Inc. (VM4) stock considered safe havenBond Market & AI Driven Price Forecasts - newser.com
How Vanda Pharmaceuticals Inc. stock performs in interest rate cyclesMarket Volume Report & High Win Rate Trade Alerts - newser.com
How supply shortages influence Vanda Pharmaceuticals Inc. (VM4) stock2025 Top Gainers & Verified Entry Point Signals - newser.com
Vanda Pharmaceuticals (VNDA): Forecasts See Earnings Growth of 68.5% Annually Heading Into Earnings Season - Sahm
Vanda Pharmaceuticals (VNDA): Revenue Projected to Grow 22.7% Annually, Profitability in Focus Ahead of Earnings - Yahoo Finance
Vanda Pharmaceuticals Inc (VNDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Vanda Pharmaceuticals Inc. (VNDA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Vanda Pharmaceuticals Inc (VNDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses - GuruFocus
VNDA Analyst Rating Update: Cantor Fitzgerald Adjusts Price Target | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Vanda Sees Sales Jump, But Losses Also Pile Up - Finimize
Vanda: Q3 Earnings Snapshot - CT Insider
Vanda Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vanda Pharmaceuticals Q3 2025 Earnings: EPS of -$0.38 Beats Esti - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):